Humanized CAR binding domains to minimize immunogenicity Ultra-modular CAR design to enhance efficacy and function Multi-step safety switch to enhance safety and physician control Ultra-fast manufacture: the first ‘24-hour CAR-T product’

OUR FOCUS

T-CURX develops a new generation of T cells for personalized cancer immunotherapy, built on a proprietary platform that overcome challenges in safety & efficacy, manufacture & scalability that are restraining the use of conventional CAR-T cells.

The T cell technology platform includes virus-free gene transfer and optimizes the binding of a chimeric-antigen-receptors to its antigen using a new and proprietary CAR format.

CAR-T cells are a transformative, one-shot, chemotherapy-free cancer treatment. Patient T cells are reprogrammed using gene transfer technology to destroy tumor cells. CAR-T cells are ‘living drugs’ that persist life-long and provide protection from relapse.

T-CURX’ target pipeline addresses several cancer indications such as multiple myeloma and acute myeloid leukemia (hematology), breast cancer, lung cancer and pancreatic cancer (oncology).

Key facts

Indication

Status

Intellectual Property status

Milestones